Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value
$28.26+0.73 (+2.65%)
Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –
Arcutis Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Arcutis Biotherapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $93.86M, up 32.0% year over year. For fiscal 2025 it was $77.05M, up 0.8% from the year before. The highest annual figure on record is $182.44M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.05M | +0.8% |
| FY2024 | Dec 31, 2024 | $76.42M | -30.9% |
| FY2023 | Dec 31, 2023 | $110.58M | -39.4% |
| FY2022 | Dec 31, 2022 | $182.44M | +25.3% |
| FY2021 | Dec 31, 2021 | $145.56M | +26.2% |
| FY2020 | Dec 31, 2020 | $115.31M | +215.7% |
| FY2019 | Dec 31, 2019 | $36.52M | +103.6% |
| FY2018 | Dec 31, 2018 | $17.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $22.42M | +14.4% |
| Q2 FY2026 | Jun 30, 2026 | $20.36M | +4.6% |
| Q1 FY2026 | Mar 31, 2026 | $30.63M | +74.6% |
| Q4 FY2025 | Dec 31, 2025 | $20.45M | +41.2% |
| Q3 FY2025 | Sep 30, 2025 | $19.60M | +0.5% |
| Q2 FY2025 | Jun 30, 2025 | $19.45M | +0.8% |
| Q1 FY2025 | Mar 31, 2025 | $17.54M | -24.2% |
| Q4 FY2024 | Dec 31, 2024 | $14.48M | -39.1% |
| Q3 FY2024 | Sep 30, 2024 | $19.50M | -25.7% |
| Q2 FY2024 | Jun 30, 2024 | $19.30M | -23.5% |
| Q1 FY2024 | Mar 31, 2024 | $23.14M | -34.5% |
| Q4 FY2023 | Dec 31, 2023 | $23.78M | -29.8% |
| Q3 FY2023 | Sep 30, 2023 | $26.24M | -62.4% |
| Q2 FY2023 | Jun 30, 2023 | $25.22M | -34.0% |
| Q1 FY2023 | Mar 31, 2023 | $35.35M | -13.0% |
| Q4 FY2022 | Dec 31, 2022 | $33.88M | -35.5% |
| Q3 FY2022 | Sep 30, 2022 | $69.73M | +71.7% |
| Q2 FY2022 | Jun 30, 2022 | $38.21M | +24.2% |
| Q1 FY2022 | Mar 31, 2022 | $40.62M | +87.8% |
| Q4 FY2021 | Dec 31, 2021 | $52.56M | +92.0% |
| Q3 FY2021 | Sep 30, 2021 | $40.60M | +24.0% |
| Q2 FY2021 | Jun 30, 2021 | $30.77M | +2.5% |
| Q1 FY2021 | Mar 31, 2021 | $21.63M | -14.1% |
| Q4 FY2020 | Dec 31, 2020 | $27.37M | +154.5% |
| Q3 FY2020 | Sep 30, 2020 | $32.74M | +165.2% |
| Q2 FY2020 | Jun 30, 2020 | $30.01M | +316.0% |
| Q1 FY2020 | Mar 31, 2020 | $25.18M | +306.0% |
| Q4 FY2019 | Dec 31, 2019 | $10.76M | – |
| Q3 FY2019 | Sep 30, 2019 | $12.35M | – |
| Q2 FY2019 | Jun 30, 2019 | $7.21M | – |
| Q1 FY2019 | Mar 31, 2019 | $6.20M | – |
See a number that looks wrong?